期刊
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
卷 19, 期 4, 页码 340-349出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1074248414527641
关键词
cardiomyopathies; cardiomyopathy; heart disease; stem cells therapy
资金
- NIH/NHBI [U01 HL099776]
- NIH Director's New Innovator Award [DP2 OD004411]
- California Institute of Regenerative Medicine [RB3-05129]
- Endowed Faculty Scholar Award from Child Health Research Institute
- Lucile Packard Foundation for Children at Stanford
Ischemic cardiac disease is the leading cause of death in the developed world. The inability of the adult mammalian heart to adequately repair itself has motivated stem cell researchers to explore various strategies to regenerate cardiomyocytes after myocardial infarction. Over the past century, progressive gains in our knowledge about the cellular mechanisms governing fate determination have led to recent advances in cellular reprogramming. The identification of specific factors capable of inducing pluripotent phenotype in somatic cells as well as factors that can directly reprogram somatic cells into cardiomyocytes suggests the potential for these approaches to translate into clinical therapies in the future. Although conceptually appealing, the field of cell lineage reprogramming is in its infancy, and further research will be needed to improve the efficiency of the reprogramming process and the fidelity of the reprogrammed cells to their in vivo counterpart.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据